Clinical trial
A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD
NCT00174525 is registered in ClinicalTrials.gov with Pharmacology Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD
- Lead sponsor
- Pharmacology Research Institute
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- April 30, 2005
- Completion date
- April 30, 2008
- Enrollment
- Not reported
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
alzheimer's disease